A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
National Institutes of Health Clinical Center (CC)
Coherus Oncology, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
City of Hope Medical Center
Tesaro, Inc.
Toray Industries, Inc
Shanghai Junshi Bioscience Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Emory University
Canadian Cancer Trials Group
Eli Lilly and Company
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota